Laurus Labs Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Laurus Labs Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Laurus Labs Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Laurus Labs Private Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $1.1M Total Trade · DGFT Verified

Laurus Labs Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 23 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Dolutegravir ($900.0K), Emtricitabine ($250.0K), .

Laurus Labs Private Limited — Export Portfolio & Destination Treemap

Laurus Labs Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Laurus Labs Private Limited? — Company Overview & Market Position

Laurus Labs Private Limited, established in September 2005, is a prominent Indian pharmaceutical company headquartered in Hyderabad, Telangana. The company specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical formulations. Laurus Labs operates under the Corporate Identification Number (CIN) U24239AP2005PTC047518. As of 2022, the company employs approximately 6,167 individuals, reflecting its significant presence in the pharmaceutical industry. The company's official website is www.lauruslabs.com.

What Does Laurus Labs Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dolutegravir$900.0K 2Emtricitabine$250.0K

Laurus Labs Private Limited Therapeutic Categories — 1 Specializations

Laurus Labs Private Limited operates across 1 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

Laurus Labs Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dolutegravir	Antiviral & HIV Medications	$900.0K	18	0.0%	10
2	Emtricitabine	Antiviral & HIV Medications	$250.0K	5	0.2%	13

Laurus Labs Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $1.1M. The top category is Antiviral & HIV Medications (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Laurus Labs Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Laurus Labs operates multiple manufacturing facilities across India, including locations in Visakhapatnam, Hyderabad, and Bangalore. These facilities are equipped to produce a wide range of pharmaceutical products, including APIs and finished dosage forms. The manufacturing units have received approvals from various global regulatory agencies, such as the US FDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at Laurus Labs is headed by CEO and Whole-Time Director Dr. Satyanarayana Chava, who founded the company in 2005. Vantaram Venkata Ravi Kumar serves as the Chief Financial Officer and Whole-Time Director. Other key executives include B. V. R. K. Suryadevara Srinivasa Rao, President of Manufacturing and Operations, and Gogireddy Venkateswar Reddy, Vice President of Legal, Compliance Officer, and Company Secretary.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Laurus Labs Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Laurus Labs has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have received approvals from the US FDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA, facilitating market access in these regions. In March 2020, Laurus Labs received US FDA approval to market hydroxychloroquine tablets, which were supplied for clinical trials of preventive treatment of COVID-19.

2Emerging Markets

Laurus Labs has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards and regulatory approvals, such as those from the WHO, has enabled it to access these markets effectively. The establishment of subsidiaries in Europe and the United States further supports its global expansion strategy.

3Geographic Strategy

Laurus Labs has strategically diversified its operations across multiple geographies, including India, the United States, Europe, and emerging markets in Africa, Latin America, and Southeast Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The company's global footprint is supported by manufacturing facilities approved by international regulatory agencies, ensuring compliance with global standards.

Laurus Labs Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Laurus Labs' manufacturing facilities have been inspected and approved by the US FDA, reflecting the company's commitment to maintaining high-quality standards. In March 2020, the company received US FDA approval to market hydroxychloroquine tablets, which were supplied for clinical trials of preventive treatment of COVID-19. The company's adherence to FDA regulations underscores its capability to meet stringent quality requirements for the US market.

2WHO & EU GMP

Laurus Labs' manufacturing facilities have received approvals from the World Health Organization (WHO) and the European Union's Good Manufacturing Practice (EU GMP) standards. These certifications validate the company's commitment to producing high-quality pharmaceutical products that meet international standards. The company's adherence to WHO and EU GMP guidelines facilitates its market access in various regions, including Europe and other global markets.

3CDSCO & Indian Regulatory

Laurus Labs Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Laurus Labs operates in a competitive landscape with several key players in the pharmaceutical industry. Top competitors include Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Piramal Pharma Ltd, and Granules India Ltd. While specific market share data is not available, Laurus Labs' focus on high-quality APIs and finished formulations, along with its global manufacturing capabilities, positions it as a significant competitor in the industry.

2Key Differentiators

Laurus Labs differentiates itself through its strong focus on research and development, enabling the company to offer a diverse portfolio of APIs and finished formulations across various therapeutic areas, including anti-retroviral, oncology, cardiovascular, and gastro therapeutics. The company's integrated Contract Development and Manufacturing Organization (CDMO) services provide end-to-end solutions from clinical phase drug development to commercial manufacturing. Additionally, Laurus Labs' commitment to sustainable and efficient manufacturing processes, backed by a robust regulatory compliance track record, enhances its competitive advantage.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Laurus Labs Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Laurus Labs has a strong track record in the pharmaceutical industry, with a focus on high-quality manufacturing and regulatory compliance. The company's manufacturing facilities have received approvals from various global regulatory agencies, including the US FDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA, indicating a consistent commitment to quality standards. The company's diversified product portfolio and global manufacturing capabilities underscore its reliability as a supplier in the pharmaceutical sector.

2Certifications to Verify

Importers should verify the following certifications when considering products from Laurus Labs:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book or that the manufacturing facility is registered with the FDA.

WHO-GMP Certification: Check for a valid WHO-GMP certificate issued to the manufacturing facility.

Frequently Asked Questions — Laurus Labs Private Limited

How many pharmaceutical products does Laurus Labs Private Limited export from India?

Laurus Labs Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Dolutegravir ($900.0K), Emtricitabine ($250.0K). Total export value is $1.1M.

What is Laurus Labs Private Limited's total pharmaceutical export value?

Laurus Labs Private Limited's total pharmaceutical export value is $1.1M, based on 23 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Laurus Labs Private Limited cover?

Laurus Labs Private Limited exports across 1 therapeutic categories. The largest are Antiviral & HIV Medications (100.0%, 2 products).

Get Full Laurus Labs Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.